1. Home
  2. RYTM vs NCLH Comparison

RYTM vs NCLH Comparison

Compare RYTM & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$104.05

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Logo Norwegian Cruise Line Holdings Ltd.

NCLH

Norwegian Cruise Line Holdings Ltd.

SELL

Current Price

$17.59

Market Cap

7.1B

ML Signal

SELL

Company Overview

Basic Information
Metric
RYTM
NCLH
Founded
2008
1966
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Marine Transportation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
7.1B
IPO Year
2017
2011

Fundamental Metrics

Financial Performance
Metric
RYTM
NCLH
Price
$104.05
$17.59
Analyst Decision
Strong Buy
Buy
Analyst Count
19
26
Target Price
★ $140.29
$19.57
AVG Volume (30 Days)
1.1M
★ 20.3M
Earning Date
11-03-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 28.34
N/A
EPS
N/A
★ 1.77
Revenue
N/A
★ $5,396,175,000.00
Revenue This Year
$73.80
$2.76
Revenue Next Year
$73.86
$4.94
P/E Ratio
★ N/A
$10.51
Revenue Growth
N/A
★ 10.71
52 Week Low
$74.50
$13.63
52 Week High
$122.20
$25.13

Technical Indicators

Market Signals
Indicator
RYTM
NCLH
Relative Strength Index (RSI) 70.69 68.92
Support Level $98.83 $18.13
Resistance Level $117.84 $19.12
Average True Range (ATR) 5.13 0.68
MACD 1.91 0.33
Stochastic Oscillator 94.41 99.46

Price Performance

Historical Comparison
RYTM
NCLH

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About NCLH Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 75,000). It operates 35 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet after the pandemic as of May 2022. With 16 passenger vessels on order among its brands through 2037, representing 43,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.

Share on Social Networks: